HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Recent Analyst Ratings for Halozyme Therapeutics Inc.

Date	Price Target	Rating	Analyst
5/14/2025	$62.00	Overweight → Equal-Weight	Morgan Stanley
5/13/2025	$47.00	Market Perform → Underperform	Leerink Partners
10/7/2024	$58.00 → $62.00	Overweight → Equal Weight	Wells Fargo
9/19/2024	$52.00 → $57.00	Overweight → Neutral	JP Morgan
6/7/2024	$48.00 → $51.00	Overweight → Neutral	Piper Sandler
2/29/2024	$54.00	Outperform	TD Cowen
7/24/2023	$61.00	Buy	H.C. Wainwright
7/24/2023	$43.00 → $45.00	Buy → Neutral	Goldman
5/10/2023	$46.00	Neutral → Overweight	Piper Sandler
3/27/2023	$58.00	Buy	Berenberg

See more ratings

Halozyme Therapeutics Inc.

Peers

Recent Analyst Ratings for Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, CHIEF LEGAL OFFICER Snyder Mark Howard covered exercise/tax liability with 2,711 shares and converted options into 5,035 shares, increasing direct ownership by 8% to 30,813 units (SEC Form 4)

Director Posard Matthew L. was granted 4,165 shares, increasing direct ownership by 6% to 74,039 units (SEC Form 4)

Director Miyashita Akiko Moni was granted 4,165 shares, increasing direct ownership by 20% to 24,937 units (SEC Form 4)

Director Krishnan Mahesh was granted 4,165 shares, increasing direct ownership by 64% to 10,666 units (SEC Form 4)

Director Henderson Jeffrey William was granted 4,165 shares, increasing direct ownership by 15% to 32,776 units (SEC Form 4)

Director Duncan Barbara Gayle was granted 4,165 shares, increasing direct ownership by 26% to 19,919 units (SEC Form 4)

Director Connaughton Bernadette was granted 4,165 shares, increasing direct ownership by 9% to 50,952 units (SEC Form 4)

Director Henderson Jeffrey William sold $271,467 worth of shares (4,497 units at $60.37), decreasing direct ownership by 14% to 28,611 units (SEC Form 4)

Director Henderson Jeffrey William sold $32,217 worth of shares (503 units at $64.05), decreasing direct ownership by 1% to 33,108 units (SEC Form 4)

Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4)